Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Sage Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Sage Therapeutics has a total shareholder equity of $628.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $697.1M and $69.0M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$646.79m |
| Eşitlik | US$628.06m |
| Toplam yükümlülükler | US$69.04m |
| Toplam varlıklar | US$697.11m |
Son finansal sağlık güncellemeleri
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Recent updates
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge
Aug 30Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)
Jul 25Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price
Jul 13Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data
May 30Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?
May 21Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%
Feb 22Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)
Feb 15Sizing Up Sage Therapeutics
Jan 22Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade
Aug 09Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Feb 22An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued
Nov 12Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation
Oct 14Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M
Aug 02We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Jun 15Sage Therapeutics: Well-Funded But Uninspiring Data
Mar 24We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely
Feb 26Sage Therapeutics: Biogen's Backing May See It Through
Jan 04What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today
Aug 05Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns
Jul 25Sage Therapeutics Needs To Show Improved Data To Regain Investor Trust
Jul 12Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: SAGE's short term assets ($686.8M) exceed its short term liabilities ($69.0M).
Uzun Vadeli Yükümlülükler: SAGE has no long term liabilities.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: SAGE is debt free.
Borcun Azaltılması: SAGE has not had any debt for past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: SAGE has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if SAGE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.